10-K: Orgenesis Inc. Reports Full Year 2023 Results, Navigates Financial Challenges

Orgenesis Inc. released its 2023 annual report, highlighting a significant decrease in revenue and ongoing financial uncertainties.

Summary

• Orgenesis Inc. reported a substantial decrease in revenue for the year ended December 31, 2023, with total revenue dropping to $530 thousand from $36,025 thousand in 2022.
• The company experienced a significant operating loss of $53,636 thousand in 2023, compared to $10,110 thousand in 2022.
• A net loss of $64,918 thousand was recorded for 2023, a considerable increase from the $12,169 thousand net loss in 2022.
• The company's management and independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is actively seeking additional capital through equity or debt financing to support its operations and address its financial challenges.
• The company's POCare business model faces significant challenges, including an unproven business model and a rapidly evolving cell therapy industry.
• The company is focused on expanding its POCare network and developing advanced therapies, but faces risks related to regulatory approvals, intellectual property, and competition.

Sentiment

Score: 3

Explanation: The document presents a concerning financial situation with significant losses and doubts about the company's ability to continue as a going concern. While there are some positive aspects related to the company's technology and collaborations, the overall sentiment is negative due to the financial challenges and risks.

Positives

• The company is actively working to expand its POCare network and develop advanced therapies.
• The company has a diverse pipeline of cell and gene therapies in development.
• The company has established POCare Centers in several locations globally.
• The company has a collaborative network of research institutes and hospitals.

Negatives

• The company experienced a significant decrease in revenue and a substantial increase in net loss.
• The company's POCare business model has a limited operating history and faces significant challenges.
• The company has identified a material weakness in its internal control over financial reporting.
• The company's management and independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company is facing significant competition from other biotechnology and pharmaceutical companies.

Risks

• The company's ability to continue as a going concern is uncertain.
• The company may not be able to obtain additional capital on acceptable terms or at all.
• The company's research and development efforts are based on novel technologies and are inherently risky.
• The company's success depends on strategic collaborations with third parties, and it may not have control over key elements of development and commercialization.
• The company's success depends on its ability to protect its intellectual property and proprietary technologies.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company is highly dependent on key personnel who would be difficult to replace.
• The company's operations in Israel may be affected by political and military conditions.
• The company's product candidates may cause undesirable side effects or have other properties that could halt their clinical development.
• The company's product candidates are biologics, and the manufacture of its product candidates is complex.

Future Outlook

The company intends to continue improving the net results in its POCare business into fiscal year 2024 and is planning to raise additional capital to continue its operations and to repay its outstanding loans when they become due, as well as to explore additional avenues to increase revenues and reduce expenditures.

Management Comments

• Management is unable to predict if and when we will be able to generate significant revenues or achieve profitability.
• Management is unable to predict if and when we will be able to generate significant revenues or achieve profitability.

Industry Context

The global CGT market is growing rapidly, with over 2,000 active clinical trials, but the industry faces challenges in scaling production and reducing costs. Orgenesis is attempting to address these challenges with its POCare platform.

Comparison to Industry Standards

• The company's financial results are significantly below industry standards for revenue generation and profitability.
• Many biotech companies developing CGTs have been acquired by large pharma for several billion dollars before generating their first revenues, indicating the high value placed on promising CGT technologies.
• The company's approach to decentralized cell processing is unique and not directly comparable to traditional centralized manufacturing models used by most CGT companies.
• The company's focus on autologous therapies aligns with a growing segment of the ATMP market, but the company's ability to compete with larger, better-capitalized companies remains a challenge.

Management Changes

Legal Proceedings

• The company is involved in a legal proceeding with Tel Hashomer Medical Research, Infrastructure and Services Ltd. regarding royalty payments.
• The company is involved in a legal proceeding with Ehud Almon regarding finders fees and/or royalties.
• The company is involved in a legal proceeding with Southern Israel Bridging Fund Two LP and Mr. Amir Hasidim regarding a convertible loan agreement.
• The company is involved in a legal proceeding with Fidelity Venture Capital Ltd. and Dror Atzmon regarding an unsecured convertible note agreement and a consultation agreement.
• The district court in Haifa appointed a trustee to run the affairs of Orgenesis Biotech Israel Limited (OBI) with the intention of rehabilitating OBI.

Related Party Transactions

• The company has related party transactions with Octomera LLC, including loans and investments.
• The company has related party transactions with its executive officers and directors, including compensation and stock-based awards.

Stakeholder Impact

• Shareholders face significant risks due to the company's financial challenges and uncertainties.
• Employees may be affected by potential cost-cutting measures and restructuring.
• Customers may experience disruptions in services due to the company's financial instability.
• Suppliers and creditors may face increased risks of non-payment.
• The company's ability to deliver on its mission of affordable and accessible cell and gene therapies may be impacted.

Next Steps

• The company plans to continue improving the net results in its POCare business into fiscal year 2024.
• The company plans to raise additional capital to continue its operations and to repay its outstanding loans when they become due.
• The company plans to explore additional avenues to increase revenues and reduce expenditures.

Key Dates

Keywords

cell therapy, gene therapy, POCare, biotechnology, clinical trials, revenue, financial results, intellectual property, regulatory approval, OMPULs